Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of MK0736 & MK0916 in Patients With Hypertension (High Blood Pressure)(0736-003)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Hypertension systolic blood pressure (SBP) \</= 160mm Hg and diastolic blood pressure (DBP): 90-105mm Hg~Exclusion Criteria:~* Pre-menopausal women~* patients currently taking more than two (2) blood pressure lowering medications~* Body Mas Index (BMI)\>40 kg/m2 (morbidly obese patients)~* History of Alcohol abuse (\<3 Years)~* History of diabetes,chronic kidney disease, Active liver disease, recent heart attack or stroke

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- High BMI:MK-0736 2mg→Placebo (Type: EXPERIMENTAL): Participants administered MK-0736 2mg tablet once daily for 12 weeks (Phase A) then administered placebo once daily for 12 weeks (Phase B)
- High BMI:MK-0736 7mg→Placebo (Type: EXPERIMENTAL): Participants administered MK-0736 7mg tablet once daily for 12 weeks (Phase A) then administered placebo once daily for 12 weeks (Phase B)
- High BMI:MK-0916 6mg→MK-0916 6mg (Type: EXPERIMENTAL): Participants administered MK-0916 6mg tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)
- High BMI:Placebo→Placebo (Type: PLACEBO_COMPARATOR): Participants administered placebo tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)
- Low BMI:MK-0916 6mg→MK-0916 6mg (Type: EXPERIMENTAL): Participants administered MK-0916 6mg tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)
- Low BMI:Placebo→Placebo (Type: PLACEBO_COMPARATOR): Participants administered placebo tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)

Based on this trial design, predict the completion outcome and termination type (if applicable).